Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 2, 2003, Pages 373-378

  Vree, Tom B ^a   Dammers, Erik ^b   Exler, Peter S ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DADA Consultancy   (Netherlands)

^c Disphar International ^*  (Netherlands)

Author keywords

Amoxicillin clavulanate; Amoxicillin clavulanate ratio; Amoxiclav; AUC; Co amoxiclav; Pharmacokinetics; Variable absorption

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CLAVULANATE POTASSIUM;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; META ANALYSIS; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; CLAVULANIC ACID; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY;

EID: 0037328859     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg082     Document Type: Article

References (28)

1. Fisher, J., Charnas, R. L. & Knowles, J. R. (1978). Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid. Biochemistry 17, 2180-4.
2. Reading, C. & Cole, M. (1977). Clavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrobial Agents and Chemotherapy 11, 852-7.
3. Witkowski, G., Lode, H., Höffken, G. & Koeppe, P. (1982). Pharmacokinetic studies of amoxicillin, potassium clavulanate and their combination. European Journal of Clinical Microbiology 1, 233-7.
4. Staniforth, D. H., Jackson, D., Horton, R. & Davies, B. (1984). Parenteral augmentin: pharmacokinetics. International Journal of Clinical Pharmacology Therapy and Toxicology 22, 430-4.
5. Todd, P. A. & Benfield, P. (1990). Amoxicillin/clavulanic acid-an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 39, 264-307.
6. Balgos, A. A., Rodriguez-Gomez, G., Nasnas, A. A., Mahashur, B. P., Margono, J. C., Tinoco-Favila, R. H. et al. (1998). A double-blind, randomized, parallel group study comparing the efficacy and safety of amoxicillin/clavulanate 875/125 mg p.o. b.i.d. versus 500/125 mg p.o. b.i.d. in the treatment of bacterial lower respiratory tract infection. In Programs and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 1998. Abstract L-110, p. 581. American Society for Microbiology, Washington, DC, USA.
7. Calver, A. D., Walsh, N. S., Quinn, P. F., Baran, C., Lonergan, V., Singh, K. P. et al. (1997). Dosing of amoxicillin/clavulanate given every 12 h is as effective as dosing every 8 h for treatment of lower respiratory tract infection. Clinical Infectious Diseases 24, 570-4.
8. Cooper, C. E., Slocombe, B. & White, A. R. (1990). Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase producing Branhamella catarrhalis and Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 26, 371-80.
9. Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S. & Craig, W. A. (1988). Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 158, 831-47.
10. Reed, M. D. (1998). The clinical pharmacology of amoxicillin and clavulanic acid. Pediatric Infectious Disease Journal 17, 957-62.
11. Reed, M. D. (1996). Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatric Infectious Disease Journal 15, 949-54.
12. Straub, R. F. & Voyksner, R. D. (1993). Determination of penicillin G, ampicillin, amoxicillin, cloxacillin and cephapirin by high-performance liquid chromatography-electrospray mass spectrometry. Journal of Chromatography 647, 167-81.
13. Suwanrumpha, S., Flory, D. A., Freas, R. B. & Vestal, M. B. (1988). Tandem mass spectrometric studies of the fragmentation of penicillins and their metabolites. Biomedical Mass Spectrometry 16, 381-6.
14. Horber, F. F., Frey, F. J., Descoeurders, C., Murray, A. T. & Reubi, F. C. (1986). Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin. Antimicrobial Agents and Chemotherapy 29, 614-9.
15. Nilsson-Ehle, I., Fellner, H., Hedström, S. A., Nilsson-Ehle, P. & Sjövall, J. (1985). Pharmacokinetics of clavulanic acid, given in combination with amoxicillin, in volunteers. Journal of Antimicrobial Chemotherapy 16, 491-8.
16. Allen, G. D., Coates, P. E. & Davies, B. E. (1988). On the absorption of clavulanic acid. Biopharmaceutics and Drug Disposition 9, 127-36.
17. Bolton, G. C., Allen, G. D., Davies, B. E., Filer, C. W. & Jeffery, D. J. (1986). The disposition of clavulanic acid in man. Xenobiotica 16, 853-63.
18. Elias Jones, A., Barnes, N. D., Tasker, T. C. G. & Horton, R. (1990). Pharmacokinetics of intravenous amoxycillin and potassium clavulanate in seriously ill children. Journal of Antimicrobial Chemotherapy 25, 269-74.
19. Neu, H. C. (1984). Beta-lactamases: a perspective on the contribution of these enzymes to bacterial resistance. Postgraduate Medicine 76, Suppl., 7-21.
20. Neu, H. C. & Fu, K. P. (1984). Clavulanic acid, a novel inhibitor of β-lactamases. Antimicrobial Agents and Chemotherapy 14, 650-5.
21. Chulavatnatol, S. & Charles, B. G. (1994). Determination of dose-dependent absorption of amoxycillin from urinary excretion data in healthy subjects. British Journal of Clinical Pharmacology 38, 274-7.
22. Sjövall, J., Alván, G. & Westerlund, D. (1985). Dose-dependent absorption of amoxycillin and bacampicillin. Clinical Pharmacology and Therapeutics 38, 241-50.
23. Vree, T. B., Dammers, E. & van Duuren, E. (2002). Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of clavubactin and synulox in healthy cats. Scientific World Journal 2, 1369-78.
24. Vree, T. B., Dammers, E. & van Duuren, E. (2002). Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of Clavubactin and Synulox in healthy dogs. Journal of Veterinary Pharmacology and Therapeutics, in press.
25. Ball, A. P., Geddes, A. & Rolinson, G. (1997). Amoxycillin clavulanate: an assessment after 15 years of clinical application. Journal of Chemotherapy 9, 167-98.
26. Hoberman, A., Paradise, J. L., Burch, D. J., Valinski, W. A., Hedrick, J. A., Aronovitz, G. H. et al. (1997). Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatric Infectious Disease Journal 16, 463-70.
27. Martin, C., Mallet, M., Sastre, B., Viviand, X., Martin, A., deMicco, P. et al. (1995). Comparison of concentrations of two doses of clavulanic acid (200 and 400 mg) administered with amoxicillin (2000 mg) in tissues of patients undergoing colorectal surgery. Antimicrobial Agents and Chemotherapy 39, 94-8.
28. Natsch, S. & van der Meer, J. W. (1998). Dosing of amoxicillin/clavulanate for treatment of lower respiratory tract infection. Clinical Infectious Diseases 26, 529-30.